Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early DOACs versus warfarin after bioprosthetic valve replacement in patients with atrial fibrillation
ChiCTR2400093549Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of warfarin in Atrial fibrillation (AFib), atrial flutter (AFL) and Cardiac valve disease (VHD) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Composite endpoint of major cardiovascular events, major bleeding events, or death. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
warfarin
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR2400093549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093549.